Literature DB >> 16312138

Retisert (Bausch & Lomb/Control Delivery Systems).

Lyndell L Lim1, Justine R Smith, James T Rosenbaum.   

Abstract

Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16312138

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

Review 1.  Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.

Authors:  R W J Lee; A D Dick
Journal:  Eye (Lond)       Date:  2011-09-30       Impact factor: 3.775

Review 2.  Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema.

Authors:  Marco Dutra Medeiros; Micol Alkabes; Paolo Nucci
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 3.  Uveitis and gender: the course of uveitis in pregnancy.

Authors:  Nathalie P Y Chiam; Lyndell L P Lim
Journal:  J Ophthalmol       Date:  2014-01-09       Impact factor: 1.909

4.  Scleral melt following Retisert intravitreal fluocinolone implant.

Authors:  Ilias Georgalas; Chrysanthi Koutsandrea; Dimitrios Papaconstantinou; Dimitrios Mpouritis; Petros Petrou
Journal:  Drug Des Devel Ther       Date:  2014-11-28       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.